- 2014
-
Press releases - 11.03.2014
Non-coding genomic regions ameliorate the severity of beta-thalassemia and sickle cell anemia
Des régions non codantes du génome semblent diminuer la sévérité de deux maladies des globules rouges : la bêta thalassémie et la drépanocytose
-
Press releases - 11.03.2014
How does light affect our brain’s performance?
Who would have thought that our brains are better equipped to process cognitive tasks if we are exposed to light several hours beforehand
-
What's on? - 05.03.2014
Semaine du cerveau (Brain awareness week) 10-16 march 2014
The 15th edition of Brain Awareness Week will take place in France and in 62 countries around the world from 10 to 16 March 2014. Throughout this week, the general public will be able to meet researchers from Inserm to gain better knowledge of the brain and become better informed about recent research in this […]
-
Press releases - 03.03.2014
Europe is joining forces against neglected parasitic diseases
The international consortium A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics), coordinated by Inserm, has just obtained funds of €6 million from the European Commission to conduct large-scale testing of innovative therapies against four neglected parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.
-
What's on? - 25.02.2014
Development of a bioartificial pancreas
European consortium BIOSID have developed a bioartificial pancreas that can directly produce insulin in the bodies of patients with type 1 diabetes, which should be tested in humans by 2015. Trials will be conducted by the team led by Eric Renard, a researcher at Inserm Unit 661, “Institute for Functional Genomics,” at Montpellier University Hospital, […]
-
Press releases - 20.02.2014
Enhancement of chemotherapy by prevention of tumour cell repair
A team of researchers directed by Frédéric Coin, Inserm Research Director at the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg (a Joint Inserm/CNRS/University of Strasbourg Research Unit), has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy.
-
News in brief - 20.02.2014
Identification of the neuronal network that controls our actions and errors
When we perform an action for a specific purpose, or in response to a stimulus, it is imperative that we be able to correct it while carrying it out if it turns out to be inappropriate. Such an ability affects the quality of our daily lives, both in our immediate motor activity (not “running” a […]
-
What's on? - 17.02.2014
HIV vaccine trial recruits 100 volunteers
Today the Vaccine Research Institute (VRI) in Créteil near Paris started to recruit 100 volunteers to evaluate a preventive HIV candidate vaccine. An innovative vaccine trial was launched by the VRI and the French National Agency for Research on AIDS and Hepatitis (ANRS). It will be based in four centres. It will be the first […]
-
Press releases - 13.02.2014
Malaria – “Wake and kill”: a new concept for the elimination of relapse
A team of researchers has succeeded in culturing the dormant hepatic stage of the malaria parasite, previously inaccessible to researchers. The initial results from this technical breakthrough have enabled the development of a new concept for the elimination of malaria relapse due to the activation of these dormant forms.
-
Press releases - 12.02.2014
Why does the brain remember dreams?
Some people remember their dreams every morning, whereas others rarely remember them. A team led by Perrine Ruby, an Inserm Researcher has studied the brain activity of these types of dreamers in order to understand the differences between them.